Northwest vs Feuerstein rhubarb round 3

|About: Northwest Biotherapeut... (NWBO)|By:, SA News Editor

Northwest Biotherapeutics (NWBO -9.9%) takes predictable exception to The Street's Adam Feuerstein regarding his bearish comments after CEO Linda Powers' DCVax presentation on March 27.

The company insists that the statistical significance of the phase 3 trial results increases its chances of success not decreases as Mr. Feuerstein asserts.

It also disputes his opinion that the trial has been poorly run.

For those of you late to the theater, here is some background.